Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to Acquire C2 CryoBalloon Technology

Core Viewpoint - Merit Medical Systems, Inc. has signed a definitive asset purchase agreement to acquire the C2 CryoBalloon™ device and related technology from Pentax of America, Inc. for a total consideration of $22 million, aiming to enhance its offerings in the gastroenterology market and improve patient outcomes [1][8]. Company Overview - Merit Medical is a global leader in healthcare technology, focusing on the development, manufacture, and distribution of proprietary medical devices used in various medical procedures [14]. - Pentax Medical, a subsidiary of the HOYA Group, specializes in flexible, reusable endoscopy solutions and is committed to delivering high-quality endoscopic equipment [15]. Acquisition Details - The acquisition includes a $19 million cash payment at closing and potential contingent payments of up to $3 million based on certain milestones [8]. - The C2 CryoBalloon device is designed to treat chronic gastroesophageal reflux disease (GERD) and other gastrointestinal tissue disorders through controlled freezing treatments [3][4]. Market Impact - The acquisition is expected to strengthen Merit's position in the multibillion-dollar gastroenterology market, providing more treatment options for patients suffering from conditions like Barrett's esophagus [5][9]. - The C2 CryoBalloon is projected to contribute approximately $1 million in revenue from November 1, 2025, to December 31, 2025, and is expected to generate between $6 million to $8 million in revenue for the twelve months ending December 31, 2026 [8][9]. Financial Projections - The acquisition is anticipated to dilute Merit's non-GAAP net income and earnings per share by approximately $0.4 million and $0.01, respectively, for the initial period [8]. - For the full year 2025, the acquisition is projected to dilute GAAP net income and earnings per share by approximately $0.5 million and $0.01, respectively [8][10]. Integration Plans - Merit plans to transfer product manufacturing to its facility in South Jordan, Utah, and expects to retain some PENTAX employees involved in the C2 CryoBalloon business to leverage their expertise [7].